Details for Patent: 7,816,330

Title:	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
Abstract:	This invention relates to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
Inventor(s):	Urbanski; Maud (Flemington, NJ)
Assignee:	Janssen Pharmaceutica NV (BE)
Filing Date:	Sep 11, 2009
Application Number:	12/557,629
Claims:	1. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, comprising (a) administering to said subject a jointly effective amount of a glucose reabsorption inhibitor of formula (III) ##STR00019## wherein: X is CH, N, or C.dbd.O; R.sub.1 is H or absent; R.sub.2 is H, F, Cl, OCH.sub.3, OCH.sub.2CH.sub.3, or C.sub.1-4 alkyl, CF.sub.3, SCH.sub.3, substituted or unsubstituted phenyl or NR.sub.3R.sub.4; R.sub.3 and R.sub.4 are H, C.sub.1-C.sub.6 alkyl, or taken together with the nitrogen atom to which they are both attached form a 5-6 membered heterocyclyl with optionally 1-2 additional heteroatoms independently selected from O, S, and N; Q is --(CH.sub.2).sub.n-- where n is 1 or 2; P is H, C.sub.1-7 acyl, or (C.sub.1-6 alkoxy)carbonyl; and Z is substituted or unsubstituted, and is selected from C.sub.3-7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, and a 9- or 10-membered fused bicyclyl or fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt thereof; (b) administering to said subject a jointly effective amount of a second antidiabetic agent, and (c) administering to said subject a jointly effective amount of a third antidiabetic agent; said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect. 2. The method of claim 1, wherein the third antidiabetic agent is selected from (aa) insulins, (bb) insulin analogues; (cc) insulin secretion modulators, and (dd) insulin secretagogues. 3. The method of claim 1, wherein the second antidiabetic agent is an RXR agonist. 4. The method of claim 1, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts. 5. The method of claim 1, wherein the diabetes or Syndrome X, or associated symptoms or complication thereof is IDDM. 6. The method of claim 1, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is NIDDM. 7. The method of claim 1, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is IGT or IFG. 8. The method of claim 1, wherein R.sup.1 is H or absent. 9. The method of claim 1, wherein R.sup.2 is H, methyl, or ethyl. 10. The method of claim 1, wherein Q is --(CH.sub.2).sub.n-- and n is 1. 11. The method of claim 1, wherein Z is independently substituted with between 1 and 3 substituents independently selected from C.sub.1-4 alkoxy, phenoxy, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, halo, hydroxy, cyano, amino, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkylsulfinyl, C.sub.1-4 aminoalkyl, mono- and di(C.sub.1-4 alkyl)amino, phenyl, C.sub.1-4 alkylaminosulfonyl (SO.sub.2NHR), amino-(alkylsulfonyl) (--NHSO.sub.2R--), C.sub.1-4 dialkylaminosulfinyl (SONHRR), C.sub.1-4 alkylamido (NHCOR), C.sub.1-4 alkylcarbamido (CONHR), 5-6 membered heterocyclyl containing between 1 and 3 heteroatoms independently selected from N, S, and O; and wherein the substituent(s) on Z can be further independently substituted with between 1 and 3 substituents independently selected from C.sub.1-4 alkoxy, C.sub.1-4 alkyl, halo, hydroxy, cyano, amino, mono or di C.sub.1-4 alkyl amino and C.sub.1-4 alkylthio. 12. The method of claim 1, wherein Z is 4-substituted phenyl, 3,4-disubstituted phenyl, benzhydryl, substituted or unsubstituted thiophene, biaryl, benzofuranyl, dihydrobenzofuranyl, 4-substituted pyridyl, benzo[b]thienyl, chromanyl, benzothiophenyl, indenyl, indanyl, naphthyl, or 2,3-dihydro-benzo[1,4]dioxanyl. 13. The method of claim 1, wherein Z is unsubstituted or substituted with between 1 and 2 substituents independently selected from methoxy, ethoxy, fluoro, chloro, methyl, ethyl, propyl, butyl and isopropyl. 14. The method of claim 1, wherein Z is biphenyl, 4-(3-pyridyl)phenyl, 4-(2-thienyl)phenyl, 4-(1H-imidazole-1-yl)-phenyl, 4-(1H-pyrazol-1-yl)-phenyl, (4-ethyl)phenyl, (4-propyl)phenyl, (4-methoxyphenyl), dihydrobenzofuran-5-yl, or dihydrobenzofuran-6-yl. 15. The method of claim 1, wherein R.sub.1 is absent; X is CH and R.sub.2 is H, methyl, ethyl, or methoxy.